Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Oct 22;150(17):1315-1323.
doi: 10.1161/CIRCULATIONAHA.124.069606. Epub 2024 Apr 8.

Topical Versus Intravenous Tranexamic Acid in Patients Undergoing Cardiac Surgery: The DEPOSITION Randomized Controlled Trial

Collaborators, Affiliations
Randomized Controlled Trial

Topical Versus Intravenous Tranexamic Acid in Patients Undergoing Cardiac Surgery: The DEPOSITION Randomized Controlled Trial

André Lamy et al. Circulation. .

Abstract

Background: Although intravenous tranexamic acid is used in cardiac surgery to reduce bleeding and transfusion, topical tranexamic acid results in lower plasma concentrations compared with intravenous tranexamic acid, which may lower the risk of seizures. We aimed to determine whether topical tranexamic acid reduces the risk of in-hospital seizure without increasing the risk of transfusion among cardiac surgery patients.

Methods: We conducted a multicenter, double dummy, blinded, randomized controlled trial of patients recruited by convenience sampling in academic hospitals undergoing cardiac surgery with cardiopulmonary bypass. Between September 17, 2019, and November 28, 2023, a total of 3242 patients from 16 hospitals in 6 countries were randomly assigned (1:1 ratio) to receive either intravenous tranexamic acid (control) through surgery or topical tranexamic acid (treatment) at the end of surgery. The primary outcome was seizure, and the secondary outcome was red blood cell transfusion. After the last planned interim analysis, when 75% of anticipated participants had completed follow up, the data and safety monitoring board recommended to terminate the trial, and upon unblinding, the operations committee stopped the trial for safety.

Results: Among 3242 randomized patients (mean age, 66.0 years; 77.7% male), in-hospital seizure occurred in 4 of 1624 patients (0.2%) in the topical group, and 11 of 1628 patients (0.7%) in the intravenous group (absolute risk difference, -0.5% [95% CI, -0.9 to 0.03]; P=0.07). Red blood cell transfusion occurred in 570 patients (35.1%) in the topical group and in 433 (26.8%) in the intravenous group (absolute risk difference, 8.3% [95% CI, 5.2-11.5]; P=0.007). The absolute risk difference in transfusion of ≥4 units of red blood cells in the topical group compared with the intravenous group was 8.2% (95% CI, 3.4-12.9).

Conclusions: Among patients undergoing cardiac surgery, topical administration of tranexamic acid resulted in an 8.3% absolute increase in transfusion without reducing the incidence of seizure, compared with intravenous tranexamic acid.

Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03954314.

Keywords: administration, intravenous; administration, topical; blood transfusion; seizures; thoracic surgery; tranexamic acid.

PubMed Disclaimer

Conflict of interest statement

Dr Devereaux is employed as a professor at McMaster University. Dr Spence is employed as an anesthesiologist and intensivist at Hamilton Health Sciences and reports consultant fees from AOP Pharmaceuticals and PhaseBio outside the submitted work. Dr Whitlock reports grants from Abbott Canada during the conduct of the study and consultant fees from AtriCure Inc and Cytosorbents outside the submitted work. Dr Belley-Côté reports grants from Abbott Laboratories, Bayer, Bristol-Myers Squibb, Pfizer, and Roche Diagnostics Corporation during the conduct of the study and consultant fees from Trimedic Therapeutics outside the submitted work. Dr Arora reports other funding from Bioporto, Edwards Lifesciences, HLS Therapeutics Inc, and Renibus Therapeutics Inc outside the submitted work. The other authors report no conflicts.

Comment in

References

Publication types

MeSH terms

Associated data